Nandkumar Shinde College of Pharmacy, Aghur, Vaijapur 423701 Dist. - Aurangabad, Maharashtra.
In the developed world, extreme prematurity is the leading cause of neonatal mortality and morbidity due to a combination of organ immaturity and iatrogenic injury. Due C-Section mother go through risk like blood loss, increase infection and major risk occurs due to anesthesia given during delivery. Now AWF or artificial uterus is technique used to develop foetus outside the body. This paper elaborate detail information about technique. Artificial wombs are expensive to develop and use, meaning they may only be accessible to those who can afford it. AWF may increase existing inequalities in society. This risk may overcome due to AWF technique. AWF include various component like nutrient, oxygen supplier, uterine wall, artificial placenta (Interface), Amniotic tank and Umbilical cord. The availability of computer-controlled artificial hearts, kidneys, and lungs, as well as the possibility of implanting human embryos in ex vivo uterus models or an artificial endometrium, presents new perspectives for creating an artificial uterus. Third, I demonstrate that clinical trials will be a necessary part of the clinical translation of AWF because of requirements laid out by regulators. I consider the justification for clinical trials and highlight some of the crucial ethical questions about the conditions under which they should proceed.
S. S. Daud*, S. B. Dube, S. R. Faruki, T. A. Rajput, Ectolife –The Artificial Womb Facility, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 10, 200-204. https://doi.org/10.5281/zenodo.10031107
10.5281/zenodo.10031107
